References

Fungus Key Pro Review

Toe Nail Fungus Holistic Treatment

Get Instant Access

1. Roberts DT. Onychomycosis: current treatment and future challenges. Br J Dermatol 1999;141(Suppl. 56):1-4.

2. Zaias N. Onychomycosis. Arch Dermatol 1972; 105: 263-74.

3. Hay RJ, Baran R, Haneke E. Fungal (onychomycosis) and other infections involving the nail apparatus. In: Baran R, Dawber RPR, eds. Diseases of the nails and their management, 2nd ed. Oxford: Blackwell Scientific Publications,1994;97-134.

4. Gupta AK, Jain HC, Lynde CW et al. Prevalence and epidemiology of onychomycosis in patients visiting physicians' offices: a multicenter Canadian survey of 15,000 patients. J Am Acad Dermatol 2000;43:244-8.

5. Gupta AK, Scher RK. Management of onychomycosis: a North American perspective. Dermatol Ther 1997;3: 58-65.

6. Ghannoum MA, Hajjeh RA, Scher R et al. A large-scale North American study of fungal isolates from nails: the frequency of onychomycosis, fungal distribution, and antifungal susceptibility patterns. J Am Acad Dermatol 2000;43:641-8.

7. Gupta AK, Jain HC, Lynde CW et al. Prevalence and epidemiology of unsuspected onychomycosis in patients visiting dermatologists' offices in Ontario, Canada - a multicenter survey of 2001 patients. Int J Dermatol 1997;36:783-7.

8. Elewski BE, Charif MA. Prevalence of onychomycosis in patients attending a dermatology clinic in northeastern Ohio for other conditions. Arch Dermatol 1997;133:1172-3.

9. Sais G, Jucgla A, Peyri J. Prevalence of dermatophyte onychomycosis in Spain: a cross-sectional study. Br J Dermatol 1995;132:758-61.

10. Williams HC. The epidemiology of onychomycosis in Britain. Br J Dermatol 1993;129:101-9.

11. Gupta AK, Gupta MA, Summerbell RC et al. The epidemiology of onychomycosis: possible role of smoking and peripheral arterial disease. J Eur Acad Dermatol Venereol 2000; 14:466-9.

12. Del Mar M, De Ocariz S, Arenas R et al. Frequency of toenail onychomycosis in patients with cutaneous manifestations of chronic venous insufficiency. Int J Dermatol 2001;40:18-25.

13. Gupta AK, Taborda P, Taborda V et al. Epidemiology and prevalence of onychomycosis in HIV-positive individuals. Int J Dermatol 2000;39:746-53.

14. Gupta AK, Humke S. The prevalence and management of onychomycosis in diabetic patients. Eur J Dermatol 2000;10:379-84.

15. Gupta AK, Konnikov N, MacDonald P et al. Prevalence and epidemiology of toenail onychomycosis in diabetic subjects: a multicentre survey. Br J Dermatol 1998; 139: 665-71.

16. Gupta AK, Lynde CW, Jain HC et al. A higher prevalence of onychomycosis in psoriatics compared with non- psoriatics: a multicentre study. Br J Dermatol 1997;136:786-9.

17. Zaias N, Rebell G. Chronic dermatophytosis caused by Trichophyton rubrum. J Am Acad Dermatol 1996;35: S17-20.

18. Gupta AK. Onychomycosis in the elderly. Drugs Aging 2000;16:397-407.

19. Gupta AK, Shear NH. A risk-benefit assessment of the newer oral antifungal agents used to treat onychomycosis. Drug Saf 2000;22:33-52.

20. Hart R, Bell-Syer SE, Crawford F et al. Systematic review of topical treatments for fungal infections of the skin and nails of the feet. BMJ 1999;319:79-82.

21. Scher RK. Onychomycosis: therapeutic update. J Am Acad Dermatol 1999;40:S21-6.

22. Elewski BE. Onychomycosis: pathogenesis, diagnosis, and management. Clin Microbiol Rev 1998;11:415-29.

23. Gupta AK, Scher RK, De Doncker P. Current management of onychomycosis. An overview. Dermatol Clin 1997;15:121-35.

24. Hay RJ. Onychomycosis. Agents of choice. Dermatol Clin 1993;11:161-9.

25. Haneke E. Fungal infections of the nail. Semin Dermatol 1991;10:41-53.

26. Gupta AK, Leonardi C, Stolz R et al. Evaluation of ravuconazole for the treatment of toenail onychomycosis (abstract). Ann Dermatol Venereol 2002; 129:1S607-842.

27. Gupta AK, Fleckman P, Baran R. Ciclopirox nail lacquer topical solution 8% in the treatment of toenail onychomycosis. J Am Acad Dermatol 2000;43:S70-80.

28. Haria M, Bryson HM. Amorolfine. A review of its pharmacological properties and therapeutic potential in the treatment of onychomycosis and other superficial fungal infections. Drugs 1995;49:103-20.

29. Dermik Laboratories Inc. Ciclopirox topical solution 8% nail lacquer. Berwyn, PA, USA: Dermik Laboratories Inc., 2000.

30. Dawber RPR, De Berker D, Baran R. Science of the nail apparatus. In: Baran R, Dawber RPR, eds. Diseases of the nails and their management, 2nd ed. Oxford: Blackwell Scientific Publications,1994;1-34.

31. Scher RK. Onychomycosis is more than a cosmetic problem. Br J Dermatol 1994;130(Suppl. 43):15.

32. Drake LA, Patrick DL, Fleckman P et al. The impact of onychomycosis on quality of life: development of an international onychomycosis-specific questionnaire to measure patient quality of life. J Am Acad Dermatol 1999;41:189-96.

33. Drake LA, Shear NH, Arlette JP et al. Oral terbinafine in the treatment of toenail onychomycosis: North American multicenter trial. J Am Acad Dermatol 1997;37:740-5.

34. Scher RK, Breneman D, Rich P et al. Once-weekly fluconazole (150, 300, or 450 mg) in the treatment of distal subungual onychomycosis of the toenail. J Am Acad Dermatol 1998;38:S77-86.

35. Evans EG, Sigurgeirsson B. Double blind, randomised study of continuous terbinafine compared with intermittent itraconazole in treatment of toenail onychomycosis. The LION Study Group. BMJ 1999;318:1031-5.

36. Albanese G, Di Cintio R, Martini C, Nicoletti A. Short therapy for tinea unguium with terbinafine: four different courses of treatment. Mycoses 1995;38:211-14.

37. Andre J, De Doncker P, Laporte M et al. Onychomycosis caused by Microsporum canis: treatment with itraconazole. J Am Acad Dermatol 1995;32:1052-3.

38. Arenas R, Fernandez G, Dominguez L. Onychomycosis treated with itraconazole or griseofulvin alone with and without a topical antimycotic or keratolytic agent. Int J Dermatol 1991;30:586-9.

39. Arenas R, Dominguez-Cherit J, Fernandez LM. Open randomized comparison of itraconazole versus terbinafine in onychomycosis. Int J Dermatol 1995;34:138-43.

40. Assaf RR, Elewski BE. Intermittent fluconazole dosing in patients with onychomycosis: results of a pilot study. J Am Acad Dermatol 1996;35:216-19.

41. Bahadir S, Inaloz HS, Alpay K et al. Continuous terbinafine or pulse itraconazole: a comparative study on onychomycosis. J Eur Acad Dermatol Venereol 2000;14:422-3.

42. Baran R, Feuilhade M, Combernale P et al. A randomized trial of amorolfine 5% solution nail lacquer combined with oral terbinafine compared with terbinafine alone in the treatment of dermatophytic toenail onychomycoses affecting the matrix region. Br J Dermatol 2000;142:1177-83.

43. Baran R, Tosti A, Piraccini BM. Uncommon clinical patterns of Fusarium nail infection: report of three cases. Br J Dermatol 1997; 136:424-7.

44. Baudraz-Rosselet F, Rakosi T, Wili PB, Kenzelmann R. Treatment of onychomycosis with terbinafine. Br J Dermatol 1992;126(Suppl. 39):40-6.

45. Bentley-Phillips B. The treatment of onychomycosis with miconazole tincture. S Afr Med J 1982;62:57-8.

46. Bohn M, Kraemer KT. Dermatopharmacology of ciclopirox nail lacquer topical solution 8% in the treatment of onychomycosis. J Am Acad Dermatol 2000;43:S57-69.

47. Bonifaz A, Carrasco-Gerard E, Saul A. Itraconazole in onychomycosis: intermittent dose schedule. Int J Dermatol 1997;36:70-2.

48. Brandrup F, Larsen PO. Long-term follow-up of toe-nail onychomycosis treated with terbinafine. Acta Derm Venereol 1997;77:238.

49. Brautigam M. Terbinafine versus itraconazole: a controlled clinical comparison in onychomycosis of the toenails. J Am Acad Dermatol 1998;38:S53-6.

50. Buck DS, Nidorf DM, Addino JG. Comparison of two topical preparations for the treatment of onychomycosis: Melaleuca alternifolia (tea tree) oil and clotrimazole. J Fam Pract 1994;38:601-5.

51. Campbell CK, Johnson EM, Warnock DW. Nail infection caused by Onychocola canadensis: report of the first four British cases. J Med Vet Mycol 1997;35:423-5.

52. Chen J, Liao W, Wen H et al. A comparison among four regimens of itraconazole treatment in onychomycosis. Mycoses 1999;42:93-6.

53. Coldiron B. Recalcitrant onychomycosis of the toenails successfully treated with fluconazole. Arch Dermatol 1992;128:909-10.

54. Cribier B, Grosshans E. [Efficacy and tolerance of terbinafine (Lamisil) in a series of 50 cases of dermatophyte onychomycoses]. Ann Dermatol Venereol 1994;121:15-20.

55. De Backer M, De Keyser P, De Vroey C, Lesaffre E. A 12-week treatment for dermatophyte toe onychomycosis: terbinafine 250 mg/day v. itraconazole 200 mg/day - a double-blind comparative trial. Br J Dermatol 1996;134 (Suppl. 46):16-17.

56. De Cuyper C. Long-term evaluation of terbinafine 250 and 500 mg daily in a 16-week oral treatment for toenail onychomycosis. Br J Dermatol 1996;135:156-7.

57. De Doncker P, Van Lint J, Dockx P, Roseeuw D. Pulse therapy with one-week itraconazole monthly for three or four months in the treatment of onychomycosis. Cutis 1995;56:180-3.

58. DiSalvo AF, Fickling AM. A case of nondermatophytic toe onychomycosis caused by Fusarium oxysporum. Arch Dermatol 1980;116:699-700.

59. Dominguez-Cherit J, Teixeira F, Arenas R. Combined surgical and systemic treatment of onychomycosis. Br J Dermatol 1999;140:778-80.

60. Downs AM, Lear JT, Archer CB. Scytalidium hyalinum onychomycosis successfully treated with 5% amorolfine nail lacquer. Br J Dermatol 1999; 140:555.

61. Eastcott DF. Terbinafine and onychomycosis. N Z Med J 1991; 104:17.

62. Effendy I, Kolczak H, Ossowski B, Hohler T. [Topical therapy of onychomycoses with 8% ciclopirox laquer. An open, non-comparative study]. Fortschr Med 1993; 111: 205-8.

63. Elewski BE. Onychomycosis caused by Scytalidium dimidiatum. J Am Acad Dermatol 1996;35:336-8.

64. Galimberti R, Kowalczuk A, Flores V, Squiquera L. Onychomycosis treated with a short course of oral terbinafine. Int J Dermatol 1996;35:374-5.

65. Galitz J. Successful treatment of onychomycosis with ciclopirox nail lacquer: a case report. Cutis 2001: 68:23-4.

66. Gianni C, Cerri A, Crosti C. Unusual clinical features of fingernail infection by Fusarium oxysporum. Mycoses 1997;40:455-9.

67. Gianni C, Cerri A, Crosti C. Non-dermatophytic 80. onychomycosis. An understimated entity? A study of 51

cases. Mycoses 2000;43:29-33.

68. Goodfield MJ, Evans EG. Combined treatment with surgery and short duration oral antifungal therapy in 81.

patients with limited dermatophyte toenail infection. J Dermatol Treat 2000; 11:259-62.

69. Goodfield MJ, Rowell NR, Forster RA et al. Treatment of dermatophyte infection of the finger- and toe-nails with 82. terbinafine (SF 86-327, Lamisil), an orally active fungicidal agent. Br J Dermatol 1989;121:753-7.

70. Goodfield MJ, Evans EG. Treatment of superficial white onychomycosis with topical terbinafine cream. Br J 83. Dermatol 1999;141:604-5.

71. Gupta AK, Gregurek-Novak T, Konnikov N et al. Itraconazole and terbinafine treatment of some nondermatophyte molds causing onychomycosis of the 84. toes and a review of the literature. J Cutan Med Surg 2001;5:206-10.

72. Gupta AK, Horgan-Bell CB, Summerbell RC. 85. Onychomycosis associated with Onychocola canadensis: ten case reports and a review of the literature. J Am Acad Dermatol 1998;39:410-17.

73. Gupta AK, De Doncker P, Haneke E. Itraconazole pulse therapy for the treatment of Candida onychomycosis. 86.

J Eur Acad Dermatol Venereol 2000;15:112-15.

74. Hay RJ, Mackie RM, Clayton YM. Tioconazole nail solution - an open study of its efficacy in onychomycosis.

Clin Exp Dermatol 1985;10:111-15. 87.

75. Hay RJ, Clayton YM, Moore MK. A comparison of tioconazole 28% nail solution versus base as an adjunct to oral griseofulvin in patients with onychomycosis. Clin

Exp Dermatol 1987; 12:175-7. 88.

76. Hiruma M, Matsushita A, Kobayashi M, Ogawa H. One week pulse therapy with itraconazole (200 mg day-1) for onychomycosis. Evaluation of treatment results according 89. to patient background. Mycoses 2001;44:87-93.

77. Kirshbaum BA. Itraconazole therapy for onychomycosis:

case reports. Cutis 1996;58:371-4. 90.

78. Koenig H, Ball C, de Bievre C. First European cases of onychomycosis caused by Onychocola canadensis. J Med Vet Mycol 1997;35:71-2.

79. Lauharanta J. Comparative efficacy and safety of 91. amorolfine nail lacquer 2% versus 5% once weekly. Clin

Exp Dermatol 1992;17(Suppl. 1):41-3.

Lebwohl MG, Daniel CR, Leyden J et al. Efficacy and safety of terbinafine for nondermatophyte and mixed nondermatophyte and dermatophyte toenail onychomycosis. Int J Dermatol 2001;40:358-60. Lecha M. Amorolfine and itraconazole combination for severe toenail onychomycosis; results of an open randomized trial in Spain. Br J Dermatol 2001;145(Suppl. 60):21-6.

Lee KH, Kim YS, Kim MS et al. Study of the efficacy and tolerability of oral terbinafine in the treatment of onychomycosis in renal transplant patients. Transplant Proc 1996;28:1488-9.

Ling MR, Swinyer LJ, Jarratt MT et al. Once-weekly fluconazole (450 mg) for 4, 6, or 9 months of treatment for distal subungual onychomycosis of the toenail. J Am

Acad Dermatol 1998;38:S95-102.

Mahgoub ES. Clinical trial with clotrimazole cream (Bay b

5097) in dermatophytosis and onychomycosis.

Mycopathologia 1975;56:149-52.

Mensing H, Polak-Wyss A, Splanemann V. Determination of the subungual antifungal activity of amorolfine after

1 month's treatment in patients with onychomycosis:

comparison of two nail lacquer formulations. Clin Exp

Dermatol 1992;17(Suppl. 1):29-32.

Meyerson MS, Scher RK, Hochman LG et al. Open-label study of the safety and efficacy of Fungoid tincture in patients with distal subungual onychomycosis of the toes.

Cutis 1992;49:359-62.

Meyerson MS, Scher RK, Hochman LG et al. Open-label study of the safety and efficacy of naftifine hydrochloride 1 percent gel in patients with distal subungual onychomycosis of the fingers. Cutis 1993;51:205-7. Molin L, Tarstedt M, Engman C. Oral terbinafine treatment for toenail onychomycosis: follow-up after 5- 6 years. Br J Dermatol 2000; 143:682-3.

Moncada B, Loredo CE, Isordia E. Treatment of onychomycosis with ketoconazole and nonsurgical avulsion of the affected nail. Cutis 1983;31:438-40. Montana JB, Scher RK. A double-blind, vehicle-controlled study of the safety and efficacy of Fungoid Tincture in patients with distal subungual onychomycosis of the toes. Cutis 1994;53:313-16. Montero-Gei F, Robles-Soto ME, Schlager H. Fluconazole in the treatment of severe onychomycosis. Int J Dermatol 1996;35:587-8.

92. Nahass GT, Sisto M. Onychomycosis: successful treatment with once-weekly fluconazole. Dermatology 1993;186:59-61.

93. Ninomiya J, Yamazaki K, Ito Y et al. [Evaluation of the efficacy of small-dose itraconazole pulse therapy (200 mg/day) for tinea unguium]. Nippon Ishinkin Gakkai Zasshi 1999;40:35-7.

94. Nolting S, Brautigam M, Weidinger G. Terbinafine in onychomycosis with involvement by non-dermatophytic fungi. Br J Dermatol 1994;130(Suppl. 43):16-21.

95. Onsberg P, Stahl D, Veien NK. Onychomycosis caused by Aspergillus terreus. Sabouraudia 1978;16:39-46.

96. Onsberg P, Stahl D. Scopulariopsis onychomycosis treated with natamycin. Dermatologica 1980;160:57-61.

97. Piepponen T, Blomqvist K, Brandt H et al. Efficacy and safety of itraconazole in the long-term treatment of onychomycosis. J Antimicrob Chemother 1992;29: 195-205.

98. Piraccini BM, Morelli R, Stinchi C, Tosti A. Proximal subungual onychomycosis due to Microsporum canis. Br J Dermatol 1996;134:175-7.

99. Pittrof F, Gerhards J, Erni W, Klecak G. Loceryl nail lacquer - realization of a new galenical approach to onychomycosis therapy. Clin Exp Dermatol 1992; 17(Suppl 1):26-8.

100. Pollak R, Billstein SA. Efficacy of terbinafine for toenail onychomycosis. A multicenter trial of various treatment durations. J Am Podiatr Med Assoc 2001;91:127-31.

101. Ramos-e-Silva, Marques SA, Gontijo B et al. Efficacy and safety of itraconazole pulse therapy: Brazilian multicentric study on toenail onychomycosis caused by dermatophytes. J Eur Acad Dermatol Venereol 1998;11:109-16.

102. Reinel D, Clarke C. Comparative efficacy and safety of amorolfine nail lacquer 5% in onychomycosis, once-weekly versus twice-weekly. Clin Exp Dermatol 1992;17(Suppl. 1):44-9.

103. Reinel D. Topical treatment of onychomycosis with amorolfine 5% nail lacquer: comparative efficacy and tolerability of once and twice weekly use. Dermatology 1992;184(Suppl. 1):21-4.

104. Rollman O. Treatment of onychomycosis by partial nail avulsion and topical miconazole. Dermatologica 1982;165:54-61.

105. Rollman O, Johansson S. Hendersonula toruloidea infection: successful response of onychomycosis to nail avulsion and topical ciclopiroxolamine. Acta Derm Venereol 1987;67:506-10.

106. Romano C, Miracco C, Difonzo EM. Skin and nail infections due to Fusarium oxysporum in Tuscany, Italy. Mycoses 1998;41:433-7.

107. Romano C, Paccagnini E, Difonzo EM. Onychomycosis caused by Alternaria spp. in Tuscany, Italy from 1985 to 1999. Mycoses 2001;44:73-6.

108. Rosenthal SA, Stritzler R, Vilafane J. Onychomycosis caused by Aspergillus fumigatus. Report of a case. Arch Dermatol 1968;97:685-7.

109. Savin RC, Atton AV. Terbinafine in onychomycosis - a mini study. Int J Dermatol 1993;32:918-19.

110. Scher RK, Barnett JM. Successful treatment of Aspergillus flavus onychomycosis with oral itraconazole. J Am Acad Dermatol 1990;23:749-50.

111. Seebacher C, Nietsch KH, Ulbricht HM. A multicenter, open-label study of the efficacy and safety of ciclopirox nail lacquer solution 8% for the treatment of onychomycosis in patients with diabetes. Cutis 2001;68:17-22.

112. Segal R, Kritzman A, Cividalli L et al. Treatment of Candida nail infection with terbinafine. J Am Acad Dermatol 1996;35:958-61.

113. Shemer A, Bergman R, Cohen A, Friedman-Birnbaum R. [Treatment of onychomycosis using 40% urea with 1% bifonazole]. Harefuah 1992;122:159-60.

114. Shuster S, Munro CS. Single dose treatment of fungal nail disease. Lancet 1992;339:1066.

115. Sigler L, Congly H. Toenail infection caused by Onychocola canadensis gen. et sp. nov. J Med Vet Mycol 1990;28:405-17.

116. Sigler L, Abbott SP, Woodgyer AJ. New records of nail and skin infection due to Onychocola canadensis and description of its teleomorph Arachnomyces nodosetosus sp. nov. J Med Vet Mycol 1994;32:275-85.

117. Smith SW, Sealy DP, Schneider E, Lackland D. An evaluation of the safety and efficacy of fluconazole in the treatment of onychomycosis. South Med J 1995; 88:1217-20.

118. Syed TA, Ahmadpour OA, Ahmad SA, Shamsi S. Management of toenail onychomycosis with 2%

butenafine and 20% urea cream: a placebo-controlled, double-blind study. J Dermatol 1998;25:648-52. Syed TA, Qureshi ZA, Ali SM et al. Treatment of toenail onychomycosis with 2% butenafine and 5% Melaleuca alternifolia (tea tree) oil in cream. Trop Med Int Health 1999;4:284-7.

Tang WY, Chong LY, Leung CY et al. Intermittent pulse therapy with itraconazole for onychomycosis. Experience in Hong Kong Chinese. Mycoses 2000;43:35-9. Torok I, Simon G, Dobozy A et al. Long-term post-treatment follow-up of onychomycosis treated with terbinafine: a multicentre trial. Mycoses 1998;41:63-5. Tosti A, Piraccini BM, Stinchi C, Lorenzi S. Onychomycosis due to Scopulariopsis brevicaulis: clinical features and response to systemic antifungals. Br J Dermatol 1996;135:799-802. Tosti A, Piraccini BM. Proximal subungual onychomycosis due to Aspergillus niger: report of two cases. Br J Dermatol 1998;139:156-7. Tosti A, Piraccini BM, Lorenzi S. Onychomycosis caused by nondermatophytic molds: clinical features and response to treatment of 59 cases. J Am Acad Dermatol 2000;42:217-24.

Tseng SS, Longley BJ, Scher RK, Treiber RK. Fusarium fingernail infection responsive to fluconazole intermittent therapy. Cutis 2000;65:352-4.

Tsuboi R, Unno K, Komatsuzaki H et al. [Topical treatment of onychomycosis by occlusive dressing using bifonazole cream containing 40% urea]. Nippon Ishinkin Gakkai Zasshi 1998;39:11-16. Tulli A, Ruffilli MP, De Simone C. The treatment of onychomycosis with a new form of tioconazole. Chemioterapia 1988;7:160-3.

Ulbricht H, Worz K. [Therapy with ciclopirox lacquer of onychomycoses caused by molds]. Mycoses 1994;37(Suppl. 1):97-100.

Villars VV, Jones TC. Special features of the clinical use of oral terbinafine in the treatment of fungal diseases. Br

J Dermatol 1992;126(Suppl. 39):61-9.

Walsoe I, Stangerup M, Svejgaard E. Itraconazole in onychomycosis. Open and double-blind studies. Acta

Derm Venereol 1990;70:137-40.

Warshaw EM, Carver SM, Zielke GR, Ahmed DD.

Intermittent terbinafine for toenail onychomycosis: is it effective? Results of a randomized pilot trial. Arch Dermatol 2001; 137:1253.

132. Wong CK, Cho YL. Very short duration therapy with oral terbinafine for fingernail onychomycosis. Br J Dermatol 1995;133:329-31.

133. Wu J, Wen H, Liao W. Small-dose itraconazole pulse therapy in the treatment of onychomycosis. Mycoses 1997;40:397-400.

134. Zaias N, Serrano L. The successful treatment of finger Trichophyton rubrum onychomycosis with oral terbinafine. Clin Exp Dermatol 1989;14:120-3.

135. Zaias N, Rebell G, Zaiac MN, Glick B. Onychomycosis treated until the nail is replaced by normal growth or there is failure. Arch Dermatol2000; 136:940.

136. Gupta AK, Lynde CW, Konnikov N. Single-blind, randomized, prospective study of sequential itraconazole and terbinafine pulse compared with terbinafine pulse for the treatment of toenail onychomycosis. J Am Acad Dermatol 2001;44:485-91.

137. Drake L, Babel D, Stewart DM et al. Once-weekly fluconazole (150, 300, or 450 mg) in the treatment of distal subungual onychomycosis of the fingernail. J Am Acad Dermatol 1998;38:S87-94.

138. Haneke E, Tajerbashi M, De Doncker P, Heremans A. Itraconazole in the treatment of onychomycosis: a double-blind comparison with miconazole. Dermatology 1998;196:323-9.

139. Tausch I, Brautigam M, Weidinger G, Jones TC. Evaluation of 6 weeks treatment of terbinafine in tinea unguium in a double-blind trial comparing 6 and 12 weeks therapy. The Lagos V Study Group. Br J Dermatol 1997;136:737-42.

140. Hofmann H, Brautigam M, Weidinger G, Zaun H. Treatment of toenail onychomycosis. A randomized, double-blind study with terbinafine and griseofulvin. LAGOS II Study Group. Arch Dermatol 1995;131: 919-22.

141. Haneke E, Tausch I, Brautigam M et al. Short-duration treatment of fingernail dermatophytosis: a randomized, double-blind study with terbinafine and griseofulvin. LAGOS III Study Group. J Am Acad Dermatol 1995;32:72-7.

142. Korting HC, Schafer-Korting M, Zienicke H et al. Treatment of tinea unguium with medium and high doses of ultramicrosize griseofulvin compared with that with itraconazole. Antimicrob Agents Chemother 1993;37: 2064-8.

143. van der Schroeff JG, Cirkel PK, Crijns MB et al. A randomized treatment duration-finding study of terbinafine in onychomycosis. Br J Dermatol 1992;126(Suppl. 39):36-9.

144. Baran R, Belaich S, Beylot C et al. Comparative multicentre double-blind study of terbinafine (250 mg per day) versus griseofulvin (1 g per day) in the treatment of dermatophyte onychomycosis. J Dermatol 1997;8:93-7.

145. Goodfield MJ. Short-duration therapy with terbinafine for dermatophyte onychomycosis: a multicentre trial. Br J Dermatol 1992;126(Suppl. 39):33-5.

146. Baran R, Hay RJ, Tosti A, Haneke E. A new classification of onychomycosis. Br J Dermatol 1998;139:567-71.

147. Cox NH, Eedy DJ, Morton CA. Guidelines for management of Bowen's disease. Br J Dermatol 1999;141:633-41.

148. Gupta AK. Systemic antifungal agents. In: Wolverton SE, ed. Comprehensive Dermatologic Drug Therapy. Philadelphia: WB Saunders, 2001;55-84.

149. Faergemann J, Anderson C, Hersle K et al. Doubleblind, parallel-group comparison of terbinafine and griseofulvin in the treatment of toenail onychomycosis. J Am Acad Dermatol 1995;32:750-3.

150. Gupta AK, Sauder DN, Shear N. Antifungal agents: an overview. Part I. J Am Acad Dermatol 1994;30:677-8.

151. Gupta AK, Shear NH. The new oral antifungal agents for onychomycosis of the toenails. J Eur Acad Dermatol Venereol 1999;13:1-13.

152. Gupta AK, Sauder DN, Shear NH. Antifungal agents: an overview. Part II. J Am Acad Dermatol 1994;30:911-33.

153. Elewski BE. Once-weekly fluconazole in the treatment of onychomycosis: introduction. J Am Acad Dermatol 1998;38:S73-6.

154. De Doncker PR, Scher RK, Baran RL et al. Itraconazole therapy is effective for pedal onychomycosis caused by some nondermatophyte molds and in mixed infection with dermatophytes and molds: a multicenter study with 36 patients. J Am Acad Dermatol 1997;36:173-7.

155. Janssen Pharmaceutica Products LP. Itraconazole package insert (United States). Titusville, New Jersey, USA: Janssen Pharmaceutica, 2002.

156. Novartis Pharmaceutical Corporation. Terbinafine package insert (United States). East Hanover, New Jersey, USA: 2001.

157. Billstein S, Kianifard F, Justice A. Terbinafine v. placebo for onychomycosis in black patients. Int J Dermatol 1999;38:377-9.

158. Svejgaard EL, Brandrup F, Kragballe K et al. Oral terbinafine in toenail dermatophytosis. A double-blind, placebo-controlled multicenter study with 12 months' follow-up. Acta Derm Venereol 1997;77:66-9.

159. Watson A, Marley J, Ellis D, Williams T. Terbinafine in onychomycosis of the toenail: a novel treatment protocol. J Am Acad Dermatol 1995;33:775-9.

160. Heikkila H, Stubb S. Long-term results in patients with onychomycosis treated with terbinafine or itraconazole. Br J Dermatol 2002;146:250-3.

161. Sigurgeirsson B, Olafsson JH, Steinsson JB et al. Long-term effectiveness of treatment with terbinafine v itraconazole in onychomycosis: a 5-year blinded prospective follow-up study. Arch Dermatol 2002;138:353-7.

162. Havu V, Heikkila H, Kuokkanen K et al. A double-blind, randomized study to compare the efficacy and safety of terbinafine (Lamisil) with fluconazole (Diflucan) in the treatment of onychomycosis. Br J Dermatol 2000: 142:97-102.

163. De Backer M, De Vroey C, Lesaffre E et al. Twelve weeks of continuous oral therapy for toenail onychomycosis caused by dermatophytes: a double-blind comparative trial of terbinafine 250 mg/day versus itraconazole 200 mg/day. J Am Acad Dermatol 1998;38:S57-63.

164. Honeyman JF, Talarico FS, Arruda LHF et al. Itraconazole versus terbinafine (LAMISIL): which is better for the treatment of onychomycosis? J Eur Acad Dermatol Venereol 1997;9:215-21.

165. Degreef H, del Palacio A, Mygind S et al. Randomized double-blind comparison of short-term itraconazole and terbinafine therapy for toenail onychomycosis. Acta Derm Venereol 1999;79:221-3.

166. Brautigam M, Nolting S, Schopf RE, Weidinger G. Randomised double blind comparison of terbinafine and itraconazole for treatment of toenail tinea infection. Seventh Lamisil German Onychomycosis Study Group. BMJ 1995;311:919-22.

167. De Backer M, De Keyser P, Massart DL, Westelinck KJ. Terbinafine (Lamisil) 250 mg/day and 500 mg/day are equally effective in a 16 week oral treatment of toenail onychomycosis. A double-blind multicentre trial. In: Hay RJ, ed. International Perspective on Lamisil. London: CCT Healthcare Communications, 1994;39-43.

168. Arca E, Tastan HB, Akar A et al. An open, randomized, comparative study of oral fluconazole, itraconazole and terbinafine therapy in onychomycosis. J Dermatol Treat 2002;13:3-9.

169. Tosti A, Piraccini BM, Stinchi C et al. Treatment of dermatophyte nail infections: an open randomized study comparing intermittent terbinafine therapy with continuous terbinafine treatment and intermittent itraconazole therapy. J Am Acad Dermatol 1996;34: 595-600.

170. Alpsoy E, Yilmaz E, Basaran E. Intermittent therapy with terbinafine for dermatophyte toe-onychomycosis: a new approach. J Dermatol 1996;23:259-62.

171. Kejda J. Itraconazole pulse therapy v continuous terbinafine dosing for toenail onychomycosis. Postgrad Med 1999;Spec no.:12-15.

172. Gupta AK, Shear NH. Safety review of the oral antifungal agents used to treat superficial mycoses. Int J Dermatol 1999;38(Suppl. 2):40-52.

173. Katz HI, Gupta AK. Oral antifungal drug interactions. Dermatol Clin 1997;15:535-44.

174. Gupta AK, Katz HI, Shear N. Drug interactions with itraconazole, fluconazole and terbinafine and their management. Int J Dermatol 1999;41(2 Pt 1):237-49.

175. Novartis Pharmaceuticals Canada. Terbinafine package insert (Canada). Dorval, Quebec: Novartis Pharmaceuticals Canada, 2001.

176. Ryder NS. Terbinafine: mode of action and properties of the squalene epoxidase inhibition. Br J Dermatol 1992;126(Suppl. 39):2-7.

177. Haugh M, Helou S, Boissel JP, Cribier BJ. Terbinafine in fungal infections of the nails: a meta-analysis of randomized clinical trials. Br J Dermatol 2002; 147: 118-21.

178. Crawford F, Young P, Godfrey C et al. Oral treatments for toenail onychomycosis: a systematic review. Arch Dermatol 2002;138:811-16.

179. Odom RB, Aly R, Scher RK et al. A multicenter, placebo-controlled, double-blind study of intermittent therapy with itraconazole for the treatment of onychomycosis of the fingernail. J Am Acad Dermatol 1997;36:231-5.

180. Gupta AK, Maddin S, Arlette J et al. Itraconazole pulse therapy is effective in dermatophyte onychomycosis of the toenail: a double-blind placebo-controlled study. J Dermatol Treat 2000; 11:33-7.

181. Havu V, Brandt H, Heikkila H et al. A double-blind, randomized study comparing itraconazole pulse therapy with continuous dosing for the treatment of toe-nail onychomycosis. Br J Dermatol 1997;136:230-4.

182. Ginter G, De Doncker P. An intermittent itraconazole 1-week dosing regimen for the treatment of toenail onychomycosis in dermatological practice. Mycoses 1998;41:235-8.

183. Shemer A, Nathansohn N, Kaplan B et al. Open randomized comparison of different itraconazole regimens for the treatment of onychomycosis. J Dermatol Treat 1999;10:245-9.

184. De Doncker P, Decroix J, Pierard GE et al. Antifungal pulse therapy for onychomycosis. A pharmacokinetic and pharmacodynamic investigation of monthly cycles of 1-week pulse therapy with itraconazole. Arch Dermatol 1996;132:34-41.

185. Gupta AK, De Doncker P, Scher RK et al. Itraconazole for the treatment of onychomycosis. Int J Dermatol 1998;37:303-8.

186. Gupta AK, Albreski D, Del Rosso JQ, Konnikov N. The use of the new oral antifungal agents, itraconazole, terbinafine, and fluconazole to treat onychomycosis and other dermatomycoses. Curr Prob Dermatol 2001;13:213-48.

187. Janssen Pharmaceutica. Itraconazole package insert (Canada). Toronto, Canada: Janssen Pharmaceutica, 2001.

188. De Doncker P, Gupta AK, Cel Rosso JQ et al. Safety of itraconazole pulse therapy for onychomycosis. An update. Postgrad Med J1999;Spec no.:17-25.

189. De Doncker P, Gupta AK. Itraconazole and terbinafine in perspective. From petri dish to patient. Postgrad Med J 1999;Spec no.:6-11.

190. De Doncker P, Gupta AK, Marynissen G et al. Itraconazole pulse therapy for onychomycosis and dermatomycoses: an overview. J Am Acad Dermatol 1997;37:969-74.

191. Elewski BE, Scher RK, Aly R et al. Double-blind, randomized comparison of itraconazole capsules v. placebo in the treatment of toenail onychomycosis. Cutis 1997;59:217-20.

192. Jones HE, Zaias N. Double-blind, randomized 197. comparison of itraconazole capsules and placebo in onychomycosis of toenail. Int J Dermatol 1996;35:

193. Odom R, Daniel CR, Aly R. A double-blind, randomized comparison of itraconazole capsules and placebo in the treatment of onychomycosis of the toenail. J Am Acad Dermatol 1996;35:110-11.

194. Gupta AK, Scher RK, Rich P. Fluconazole for the 199. treatment of onychomycosis: an update. Int J Dermatol 1998;37:815-20.

195. Jansen R, Redekop WK, Rutten FF. Cost effectiveness of continuous terbinafine compared with intermittent 200. itraconazole in the treatment of dermatophyte toenail onychomycosis: an analysis of based on results from the L.I.ON. study. Lamisil versus Itraconazole in 201.

Onychomycosis. Pharmacoeconomics 2001;19:401-10.

196. Gupta AK. Pharmacoeconomic analysis of oral antifungal therapies used to treat dermatophyte 202. onychomycosis of the toenails. A US analysis. Pharmacoeconomics 1998; 13:243-56.

Marchetti A, Piech CT, McGhan WF et al. Pharmacoeconomic analysis of oral therapies for onychomycosis: a US model. Clin Ther 1996;18:757-77. Arikian SR, Einarson TR, Kobelt-Nguyen G, Schubert F. A multinational pharmacoeconomic analysis of oral therapies for onychomycosis. The Onychomycosis Study Group. Br J Dermatol 1994;130(Suppl. 43): 35-44.

Einarson TR, Arikian SR, Shear NH. Cost-effectiveness analysis for onychomycosis therapy in Canada from a government perspective. Br J Dermatol 1994;130(Suppl. 43):32-4.

Gupta AK, Baran R. Ciclopirox nail lacquer solution 8% in the 21st century. J Am Acad Dermatol 2000;43: S96-102.

Roberts DT, Evans EG. Subungual dermatophytoma complicating dermatophyte onychomycosis. Br J Dermatol 1998;138:189-90.

Gupta AK. Are boosters or supplementation of antifungal drugs of any use for treating onychomycosis? J Drugs Dermatol 2002;1:35-41.

Was this article helpful?

0 0
Supplements For Diabetics

Supplements For Diabetics

All you need is a proper diet of fresh fruits and vegetables and get plenty of exercise and you'll be fine. Ever heard those words from your doctor? If that's all heshe recommends then you're missing out an important ingredient for health that he's not telling you. Fact is that you can adhere to the strictest diet, watch everything you eat and get the exercise of amarathon runner and still come down with diabetic complications. Diet, exercise and standard drug treatments simply aren't enough to help keep your diabetes under control.

Get My Free Ebook


Post a comment